Williams L R
CNS Diseases Research, Upjohn Company, Kalamazoo, Michigan 49001.
Exp Neurol. 1991 Jul;113(1):31-7. doi: 10.1016/0014-4886(91)90143-z.
In previous experiments examining the stimulatory effect of intracerebroventricular (icv) NGF treatment on basal forebrain choline acetyltransferase (ChAT) activity, many of the rats treated with the maximally effective dose of NGF appeared gaunt compared to the vehicle-treated control animals. The present experiments determined that icv infusion of NGF at a dose of 1.2 micrograms/day causes a significant reduction in food consumption during the entire period of treatment compared to untreated and vehicle-treated animals. Male rats infused with NGF lost an average of about 30 g of body wt during the first week after the start of infusion and did not gain appreciable weight during the second week of NGF treatment. The hypophagic effect of NGF is dose-dependent, centrally mediated, and reversible. There is no correlation between the stimulatory effect of NGF on basal forebrain ChAT and the inhibitory effect of NGF on weight gain. A therapeutic dose of NGF for Alzheimer's patients comparable to the rat dose for maximally stimulating central cholinergic neurons would approach 1 mg/day. If such therapy is applied, the potential exits for induction of hypophagia as a side effect of the NGF administration.
在先前研究脑室内(icv)注射神经生长因子(NGF)对基底前脑胆碱乙酰转移酶(ChAT)活性刺激作用的实验中,与注射赋形剂的对照动物相比,许多接受最大有效剂量NGF治疗的大鼠显得消瘦。本实验确定,与未治疗和接受赋形剂治疗的动物相比,每天1.2微克剂量的icv注入NGF会导致整个治疗期间食物摄入量显著减少。注入NGF的雄性大鼠在注入开始后的第一周平均体重减轻约30克,在NGF治疗的第二周体重没有明显增加。NGF的食欲减退作用具有剂量依赖性、中枢介导性且可逆。NGF对基底前脑ChAT的刺激作用与NGF对体重增加的抑制作用之间没有相关性。与大鼠最大程度刺激中枢胆碱能神经元的剂量相当的阿尔茨海默病患者NGF治疗剂量将接近1毫克/天。如果应用这种疗法,作为NGF给药副作用的食欲减退诱导可能性存在。